NASDAQ:APTO Aptose Biosciences (APTO) Stock Forecast, Price & News $3.05 -0.06 (-1.93%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$3.02▼$3.2150-Day Range$3.04▼$5.0452-Week Range$2.91▼$11.85Volume36,714 shsAverage Volume27,728 shsMarket Capitalization$22.27 millionP/E RatioN/ADividend YieldN/APrice Target$38.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Aptose Biosciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,162.3% Upside$38.50 Price TargetShort InterestHealthy1.78% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.99Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($8.65) to ($7.14) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.70 out of 5 starsMedical Sector91st out of 963 stocksBiological Products, Except Diagnostic Industry9th out of 159 stocks 4.5 Analyst's Opinion Consensus RatingAptose Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $38.50, Aptose Biosciences has a forecasted upside of 1,162.3% from its current price of $3.05.Amount of Analyst CoverageAptose Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.78% of the float of Aptose Biosciences has been sold short.Short Interest Ratio / Days to CoverAptose Biosciences has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aptose Biosciences has recently decreased by 7.13%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAptose Biosciences does not currently pay a dividend.Dividend GrowthAptose Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for APTO. Previous Next 3.3 News and Social Media Coverage News SentimentAptose Biosciences has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Aptose Biosciences this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for APTO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows6 people have added Aptose Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aptose Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.53% of the stock of Aptose Biosciences is held by insiders.Percentage Held by InstitutionsOnly 1.07% of the stock of Aptose Biosciences is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Aptose Biosciences are expected to grow in the coming year, from ($8.65) to ($7.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aptose Biosciences is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aptose Biosciences is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAptose Biosciences has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aptose Biosciences (NASDAQ:APTO) StockAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.Read More APTO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APTO Stock News HeadlinesSeptember 21, 2023 | americanbankingnews.comShort Interest in Aptose Biosciences Inc. (NASDAQ:APTO) Decreases By 7.1%September 8, 2023 | finance.yahoo.comCompanies Like Aptose Biosciences (TSE:APS) Could Be Quite RiskySeptember 24, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.September 7, 2023 | finance.yahoo.comHANMI FILES EARLY WARNING REPORT IN RESPECT OF APTOSE BIOSCIENCES INC.September 7, 2023 | markets.businessinsider.comExpert Ratings for Aptose BiosciencesAugust 24, 2023 | finance.yahoo.comAptose to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 23, 2023 | theglobeandmail.comClosing Bell: Aptose Biosciences Inc down on Tuesday (APS)August 18, 2023 | fool.comAptose Biosciences (NASDAQ: APTO)September 24, 2023 | Legacy Research (Ad)WARNING: Mandatory U.S. Dollar Recall is Weeks AwayIf you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.August 11, 2023 | markets.businessinsider.comRBC Capital Maintains Outperform Rating for Aptose Biosciences: Here's What You Need To KnowAugust 11, 2023 | msn.comAptose Biosciences GAAP EPS of -$2.27 misses by $0.34August 2, 2023 | msn.comAptose Biosciences (APTO) Price Target Increased by 1614.75% to 62.90July 28, 2023 | finance.yahoo.comAptose to Report Second Quarter 2023 Financial Results and Hold Conference Call on Thursday, August 10, 2023June 27, 2023 | finance.yahoo.comAPTO - Aptose Biosciences Inc.June 26, 2023 | finance.yahoo.comAptose Biosciences Meets Nasdaq Minimum Bid Price ComplianceJune 12, 2023 | marketwatch.comAptose Shares Up 11% After Study Presentation, Analysts' Target BoostsJune 12, 2023 | benzinga.comOppenheimer Maintains Outperform on Aptose Biosciences, Raises Price Target to $50June 12, 2023 | benzinga.comAptose Biosciences shares are trading higher after multiple firms raised their respective price targets.June 10, 2023 | markets.businessinsider.comJonesTrading Keeps Their Buy Rating on Aptose Biosciences (APTO)June 5, 2023 | msn.comAptose Biosciences updates on reverse stock splitMay 24, 2023 | finanznachrichten.deAptose Biosciences, Inc.: Aptose Biosciences Announces Results of Annual and Special Meeting of ShareholdersMay 17, 2023 | marketwatch.comCaspase 3 Market Business Overview and Growth Forecast by 2030May 13, 2023 | theglobeandmail.comClosing Bell: Aptose Biosciences Inc down on Friday (APS)May 9, 2023 | msn.comAptose Biosciences GAAP EPS of -$0.15 misses by $0.03May 9, 2023 | markets.businessinsider.comAnalyst Expectations for Aptose Biosciences's FutureMay 9, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Aptose Biosciences (APTO)April 28, 2023 | marketwatch.comDiffuse Large B Cell Lymphoma Drug Market Outlook by 2031See More Headlines Receive APTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address APTO Company Calendar Last Earnings8/10/2023Today9/24/2023Next Earnings (Estimated)11/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APTO CUSIPN/A CIK882361 Webwww.aptose.com Phone858-926-2730Fax905-234-2120Employees31Year FoundedN/APrice Target and Rating Average Stock Price Forecast$38.50 High Stock Price Forecast$120.00 Low Stock Price Forecast$12.00 Forecasted Upside/Downside+1,162.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($7.8173) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,820,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-153.08% Return on Assets-109.40% Debt Debt-to-Equity RatioN/A Current Ratio2.11 Quick Ratio2.11 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.13 per share Price / Book0.50Miscellaneous Outstanding Shares7,300,000Free Float6,604,000Market Cap$22.27 million OptionableOptionable Beta1.38 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. William G. Rice Ph.D. (Age 59)Chairman, Pres & CEO Mr. Gregory K. Chow CPA (Age 45)MBA, BA, Sr. VP, CFO & Principal Accounting Officer Mr. Ernest Kitt B.S.M.S, VP of Devel. & Technical OperationsDr. Stephen B. Howell (Age 73)Chief Medical Officer Mr. Peter MurrayDirector of Clinical Devel.Key CompetitorsCoeptis TherapeuticsNASDAQ:COEPSenti BiosciencesNASDAQ:SNTIPluriNASDAQ:PLURPharmaCyte BiotechNASDAQ:PMCBElutiaNASDAQ:ELUTView All CompetitorsInstitutional OwnershipDRW Securities LLCSold 8,299,608 shares on 8/15/2023Ownership: 0.633%Goldman Sachs Group Inc.Sold 627,535 shares on 8/15/2023Ownership: 0.038%Carlson Capital L PSold 1,543,334 shares on 8/10/2023Ownership: 0.114%Voss Capital LLCSold 535,366 shares on 7/28/2023Ownership: 0.016%View All Institutional Transactions APTO Stock - Frequently Asked Questions Should I buy or sell Aptose Biosciences stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APTO shares. View APTO analyst ratings or view top-rated stocks. What is Aptose Biosciences' stock price forecast for 2023? 6 Wall Street research analysts have issued 1-year target prices for Aptose Biosciences' stock. Their APTO share price forecasts range from $12.00 to $120.00. On average, they predict the company's stock price to reach $38.50 in the next twelve months. This suggests a possible upside of 1,162.3% from the stock's current price. View analysts price targets for APTO or view top-rated stocks among Wall Street analysts. How have APTO shares performed in 2023? Aptose Biosciences' stock was trading at $8.70 on January 1st, 2023. Since then, APTO shares have decreased by 64.9% and is now trading at $3.05. View the best growth stocks for 2023 here. Are investors shorting Aptose Biosciences? Aptose Biosciences saw a decline in short interest in August. As of August 31st, there was short interest totaling 37,800 shares, a decline of 7.1% from the August 15th total of 40,700 shares. Based on an average daily trading volume, of 46,400 shares, the days-to-cover ratio is presently 0.8 days. Currently, 1.8% of the shares of the company are sold short. View Aptose Biosciences' Short Interest. When is Aptose Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023. View our APTO earnings forecast. How were Aptose Biosciences' earnings last quarter? Aptose Biosciences Inc. (NASDAQ:APTO) posted its quarterly earnings results on Thursday, August, 10th. The biotechnology company reported ($2.27) EPS for the quarter, missing analysts' consensus estimates of ($2.09) by $0.18. When did Aptose Biosciences' stock split? Aptose Biosciences shares reverse split before market open on Tuesday, June 6th 2023. The 1-15 reverse split was announced on Tuesday, June 6th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 6th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What is William G. Rice, Ph.D.'s approval rating as Aptose Biosciences' CEO? 8 employees have rated Aptose Biosciences Chief Executive Officer William G. Rice, Ph.D. on Glassdoor.com. William G. Rice, Ph.D. has an approval rating of 34% among the company's employees. This puts William G. Rice, Ph.D. in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 52.0% of employees surveyed would recommend working at Aptose Biosciences to a friend. What other stocks do shareholders of Aptose Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH), Arch Therapeutics (ARTH), Aurora Cannabis (ACB), NVIDIA (NVDA), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL), CymaBay Therapeutics (CBAY), Cisco Systems (CSCO), Micron Technology (MU) and SCYNEXIS (SCYX). What is Aptose Biosciences' stock symbol? Aptose Biosciences trades on the NASDAQ under the ticker symbol "APTO." Who are Aptose Biosciences' major shareholders? Aptose Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include DRW Securities LLC (0.63%), Carlson Capital L P (0.11%), Goldman Sachs Group Inc. (0.04%) and Voss Capital LLC (0.02%). Insiders that own company stock include Denis R Burger, Donald R Jr Wilson, Erich Platzer, Rafael Bejar, Warren Whitehead and William G Rice. View institutional ownership trends. How do I buy shares of Aptose Biosciences? Shares of APTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aptose Biosciences' stock price today? One share of APTO stock can currently be purchased for approximately $3.05. How much money does Aptose Biosciences make? Aptose Biosciences (NASDAQ:APTO) has a market capitalization of $22.27 million. The biotechnology company earns $-41,820,000.00 in net income (profit) each year or ($7.8173) on an earnings per share basis. How can I contact Aptose Biosciences? Aptose Biosciences' mailing address is 251 CONSUMERS ROAD SUITE 1105, TORONTO A6, M2J 4R3. The official website for the company is www.aptose.com. The biotechnology company can be reached via phone at 858-926-2730, via email at ir@aptose.com, or via fax at 905-234-2120. This page (NASDAQ:APTO) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.